NCT07319026Completed
Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis
Myeloid-derived Suppressor Cells: Characterization Of Their Role In Primary Myelofibrosis Pathogenesis For The Identification Of A New Therapeutic Target
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
The goals of this observational study are to investigate the role of myeloid-derived suppressor cells (MDSCs) in fueling chronic inflammation that is a relevant pathogenetic mechanism in patients with primary myelofibrosis (PMF), to study modifications in MDSC phenotype and function after treatment with JAK-inhibitors (JAK-i) and to test their participation in the neoangiogenic process. The main questions it aims to answer are: * Do the frequency and function of MDSCs contribute to induce or sustain the inflammatory status that characterizes PMF? * Does the number of circulating MDSCs in PMF patients correlate with clinical/biological parameters? * Are MDSCs involved in the neoangiogenic processes that characterizes PMF?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 70 (actual)
- First submitted
- 20 Nov 2025
- Start date
- 14 Nov 2023
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07319026
What you commit to
- Study type: Observational
- Participants enrolled: 70
- From 14 Nov 2023 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- concurrent or recent diagnosis of an inflammatory disease and/or neoplasia;
- concurrent pregnancy. No vulnerable participants will be enrolled in the study.
Other illness
- any other condition that can confounds the ability to interpret data from the study;
Who the study is looking for
- age \>18 years;
- diagnosis of primary myelofibrosis according to 2016 WHO criteria;
- willing to participate and understanding and signing the I.C.
Age in the registry: 18 years to 99 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.